Together to accelerate innovation
Carnot CALYM Institute promotes innovation in lymphoma research and accelerates its transfer to the clinic and the healthcare industry through public/private partnerships.
CALYM’s R&D offering is positioned in a fast-growing global pharmaceuticals and biotechnology market, which for several years has been undergoing a strategic shift involving a strong need for biological, clinical and technological expertise from the academic sector. To meet these market demands, CALYM is uniquely positioned across the entire R&D value chain, from the identification of new cellular targets to international Phase III clinical trials and beyond.
of the Carnot Calym Institute
To meet market demand, CALYM is uniquely positioned across the entire R&D value chain, from excellent fundamental research to clinical trials for drug registration.
The Carnot network is the leading player in partnership-based research in France, with 11,000 industrial R&D contracts and more than 100 high-tech start-ups launched every year. The Carnot network brings together 35,000 professionals in 39 institutes approved by the French Ministry of Research, with a key mission: to build the economic and industrial future by supporting companies in their strategies to differentiate through innovation.
CALYM is one of the Carnot Institutes with the highest volume of partnered research, the majority of which is international. A noteworthy achievement.
